Eighty-five percent of clinical trials fail to recruit enough patients, and 80% face delays from participant dropouts. These numbers have persisted for years despite growing investment in recruitment infrastructure, which means the problem isn’t a lack of effort. It’s a collection of specific, fixable barriers at every stage of the enrollment funnel, from how patients first hear about a trial to whether they can realistically show up for visits.
Why Patients Say No
Understanding what stops people from enrolling is the starting point for fixing recruitment. A pilot study published in PubMed identified the top patient-reported barriers: misperceptions about placebos, not wanting to feel like a “human guinea pig,” uncertainty about whether the experimental treatment would work as well as standard care, and concerns about extra appointments and tests. These aren’t irrational fears. They reflect a communication gap between what researchers assume patients know and what patients actually understand about how trials work.
The placebo concern is especially worth addressing head-on. Many patients believe they have a high chance of receiving a sugar pill and getting no treatment at all, when in reality most modern trials compare a new therapy against the current best treatment, not against nothing. Explaining trial design in plain terms, early in the conversation, can neutralize one of the biggest psychological barriers before it becomes a reason to decline.
Make Consent Documents Readable
Most institutional review boards recommend that informed consent forms be written at an eighth-grade reading level. In practice, almost none of them hit that target. A study in the Journal of Health Communication analyzed consent documents across multiple research sites and found the average reading level was grade 12, with some reaching grade 13. That gap between recommendation and reality means a significant share of potential participants are handed documents they can’t fully understand, then asked to sign them.
The fixes are straightforward. Use short sentences averaging 15 words or fewer. Limit each paragraph to one main idea. Replace medical jargon with plain language, and when a technical term is unavoidable, define it immediately with an example or analogy. Use at least 12-point font in a clean style like Arial, add subheadings and bullet points, and leave enough white space so the page doesn’t look like a wall of text. Documents that included what researchers call “confusion reducers” (analogies, clear pronoun references, plain vocabulary) scored significantly better on comprehension assessments. The goal is to treat the consent form as an educational tool, not a legal document.
Use Social Media to Fill the Funnel
Digital advertising, particularly on Facebook, has become one of the most cost-effective ways to reach potential participants at scale. In one large recruitment effort for a hypertension trial, Facebook campaigns reached 5.3 million people across 168 separate ad runs near 33 trial sites in the U.S. and Europe. Of those reached, 3.4% clicked the ad, 5.7% of clickers completed a screening questionnaire, and the process ultimately identified 3,632 potential candidates. The cost worked out to $0.83 per click and $828 per consented participant.
For comparison, the same study ran seven-day radio spots at a cost of $2,870, which generated just nine inquiries, five potential candidates, and two consents, putting the radio cost at $1,435 per consent. Social media didn’t just reach more people. It reached them more efficiently and at roughly half the cost per enrolled patient. Platform choice matters too: Facebook and YouTube skew older, while Instagram attracts younger users, so matching your ad platform to your target population’s demographics improves results.
Shift to Decentralized or Hybrid Models
Requiring patients to travel to a specific clinic for every visit is one of the most persistent structural barriers to enrollment. Decentralized clinical trials, which allow participants to complete some or all study activities remotely through apps, wearable devices, telehealth visits, or local lab draws, consistently outperform traditional site-based models on both recruitment speed and retention.
The evidence is striking. In a review published in the Journal of Clinical and Translational Science, eleven studies reported improved recruitment with decentralized methods, and seven of those made direct comparisons to traditional approaches. One study recruiting patients with a skin condition used Facebook ads and online study tasks, enrolling 55 participants in less than a month compared to a national median of 9.2 subjects per site per month using traditional methods. That same study reported a 96% retention rate. Another trial comparing decentralized, conventional, and mixed models found higher recruitment and 89% retention in the decentralized arm versus just 60% in the conventional arm. Virtual recruitment was also significantly faster than traditional site-based recruitment in multiple head-to-head comparisons.
The retention gains are just as important as the recruitment gains. Four studies directly compared retention between decentralized and traditional methods, and all four favored the decentralized approach. When participation is easier, fewer people drop out.
Build Physician Referral Pipelines
Many patients first learn about clinical trials from their primary care physician or specialist, which means doctors who don’t know about available trials represent a silent bottleneck. Research from Michigan State University found that primary care provider attitudes and attendance at education sessions about clinical trials consistently predicted whether they referred patients. A separate study by the Education Network to Advance Cancer Clinical Trials showed that physicians who attended an education program had statistically significant increases in both knowledge and positive attitudes about referring patients.
The practical playbook for building these relationships is straightforward: present at grand rounds, offer lunch-and-learn sessions at referring practices, and include nurses and office staff in those conversations since they often influence which information reaches patients. Once a relationship is established, maintain it through regular contact, timely progress notes on referred patients, and sharing trial results. Referring physicians are more likely to keep sending patients when they feel like partners in the research rather than a pipeline to be tapped and forgotten.
Simple asks can also move the needle. Encouraging referring doctors to introduce clinical trials as a treatment option during routine visits, provide print materials, and prompt patients to ask their specialist about trials creates multiple touchpoints before the enrollment conversation even begins.
Use AI to Match Patients Faster
One of the most time-consuming steps in recruitment is screening patients against eligibility criteria, a process that traditionally involves manual chart review. New AI systems can now evaluate a patient’s medical history, written as unstructured clinical notes, against trial inclusion criteria in seconds. A system described in NEJM AI uses large language models to perform this matching without needing to be trained on each specific trial’s criteria, achieving top performance on the largest public benchmark for clinical trial patient matching.
These tools reduce the number of hours coordinators spend on pre-screening and can surface eligible patients who might otherwise be missed, particularly in large health systems where thousands of records would be impractical to review manually. The technology works by processing clinical text and comparing it against eligibility requirements, flagging candidates for human review rather than replacing the coordinator’s judgment entirely.
Address Diversity Requirements Early
The Food and Drug Omnibus Reform Act of 2022 now requires sponsors of phase 3 drug trials and certain device studies to submit a Diversity Action Plan to the FDA. These plans must include specific enrollment goals disaggregated by race, ethnicity, sex, and age group, along with the sponsor’s rationale and strategy for meeting those goals. This isn’t optional guidance. It’s a legal requirement for late-stage trials.
Meeting these targets demands proactive planning, not last-minute outreach. Placing trial sites in communities that reflect the target demographics, partnering with community health centers, translating materials into relevant languages, and using the decentralized methods described above to reduce geographic barriers all contribute. The legislation also aligns with a broader push: if your trial population doesn’t resemble the people who will actually use the treatment, the results are less useful for everyone.
Remove Financial Barriers to Participation
Travel costs, meal expenses, lost wages, and childcare are real obstacles, especially for participants in rural areas or lower-income communities. Pending federal legislation, the Clinical Trial Modernization Act (H.R. 3521), would create a safe harbor allowing sponsors to reimburse participants for travel, transportation, and meal expenses without triggering anti-kickback violations under the Social Security Act. The bill specifies that reimbursement must be available to all study participants and must facilitate inclusion of patients from all relevant demographic and socioeconomic backgrounds, including rural communities.
The legislation would also permit free provision of digital health technologies, like remote monitoring devices or smartphone apps, when those tools are necessary for participation and intended to support underrepresented populations. Even before this bill becomes law, sponsors can design budgets that minimize out-of-pocket costs for participants through ride-share vouchers, home nursing visits, and flexible scheduling that reduces the number of in-person appointments required.